ESTRO meets Asia 2024 - Abstract Book

S269

Interdisciplinary – SBRT

ESTRO meets Asia 2024

Purpose/Objective:

Stereotactic body radiation therapy (SBRT) is a relatively novel approach for the treatment of hepatocellular carcinoma that has demonstrated impressive rates of local control and a favourable toxicity profile. It is generally utilised in patients who have undergone extensive prior treatments or are deemed ineligible for alternative local therapies. Our primary objective was to determine the local control of Hepatocellular carcinoma patients who received SBRT. The secondary objectives were to assess the Overall Survival and the impact of Portal vein involvement in both Local control and survival.

Material/Methods:

After obtaining Ethics committee approval, we looked at the medical records of 111 patients with Hepatocellular Carcinoma (HCC) who received SBRT from 2016 to 2023. Imaging at 3 –6 months post SBRT was used to assess response. Kaplan Meier plot was employed to assess Overall Survival (OS).

Results:

Median survival was around 25 months. At a mean follow up of 13 months, 9 patients were lost to follow up and 27 had expired. Of the 72 patients with available post SBRT response assessment scans, good response was noted in 23 patients, while 5 had partial response and 18 patients had stable disease. Overall Survival was lower in patients with stable response compared to those with good response. Median survival in patients with stable disease was close to 16 months. Overall survival was better in patients without vascular thrombosis than those with thrombosis as expected. Median survival in patients with thrombosis was 21 months. Overall survival was better for patients who had received TACE upfront than those who had no prior treatment. Less than 5% serious adverse events were noted during the follow up period.

Conclusion:

Due to the good local control and satisfactory overall survival, SBRT holds promise in improving the results in challenging HCC cases where alternative treatments may not suffice. Further investigation is needed to ascertain the optimal utilization of SBRT in comparison to other therapies and explore potential combination strategies.

Keywords: HCC, SBRT, Stereotactic Body Radiotherapy

References:

• Jang JY, Jung J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Park JH, Yoon SM. Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study. Journal of Liver Cancer. 2022 Sep 16;22(2):136-45. • Hu Y, Zhao C, Ji R, Chen W, Shen Q, Chiang CL, Chan J, Ma L, Yang H, Wong T, Ellsworth S. The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences. Journal of the National Cancer Center. 2022 Sep 1;2(3):171-82.